BF
Brandon Folkes HC Wainwright & Co. Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
26
Emergent Biosolutions
EBS
$403M
| $8.26 | $16 |
94%
upside
| Buy |
13 Sep ‘24
1 year ago |
|
27
CorMedix
CRMD
$952M
| $13.03 | $13 |
0%
downside
| Buy |
26 Aug ‘24
1 year ago |
|
28
Milestone Pharmaceuticals
MIST
$149M
| $1.72 | $9 |
423%
upside
| Buy |
22 Aug ‘24
1 year ago |
|
29
MannKind Corp
MNKD
$1.71B
| $5.51 | $8 |
45%
upside
| Buy |
13 Jun ‘24
1 year ago |
|
30
Trevi Therapeutics
TRVI
$926M
| $8.42 | $7 |
17%
downside
| Buy |
13 Jun ‘24
1 year ago |
|
31
Heron Therapeutics
HRTX
$199M
| $1.30 | $7 |
438%
upside
| Buy |
13 Jun ‘24
1 year ago |
|
32
Rani Therapeutics
RANI
$23.9M
| $0.4994 | $10 |
1,902%
upside
| Buy |
13 Jun ‘24
1 year ago |
|
33
Scilex Holding
SCLX
$154M
| $25.13 | $455 |
1,711%
upside
| Buy |
13 Jun ‘24
1 year ago |
|
34
Sanara MedTech
SMTI
$318M
| $34.39 | $59 |
72%
upside
| Overweight |
26 Sep ‘23
1 year ago |
|
35
Elutia
ELUT
$79.7M
| $1.48 | $8 |
441%
upside
| Overweight |
7 Sep ‘23
2 years ago |
|
36
Jazz Pharmaceuticals
JAZZ
$7.88B
| $128.53 | $180 |
40%
upside
| Overweight |
22 Aug ‘23
2 years ago |
|
37
Veru
VERU
$49.4M
| $3.47 | $220 |
6,240%
upside
| Overweight |
5 Dec ‘22
2 years ago |
|
38
Journey Medical
DERM
$184M
| $7.45 | $9 |
21%
upside
| Overweight |
25 Feb ‘22
3 years ago |
|
39
Alkermes
ALKS
$4.7B
| $27.85 | $32 |
15%
upside
| Overweight |
27 Jan ‘22
3 years ago |
|
|
RDHL
40
Redhill Biopharma
RDHL
$3.31M
| $1.42 | $22,000 |
1,549,196%
upside
| Overweight |
31 Aug ‘21
4 years ago |
|
|
41
Rani Therapeutics
RANI
$23.9M
| $0.4994 | $23 |
4,506%
upside
| Overweight |
24 Aug ‘21
4 years ago |
|
42
Collegium Pharmaceutical
COLL
$1.19B
| $37.97 | $22 |
42%
downside
| Neutral |
6 Aug ‘21
4 years ago |
|
43
PolyPid
PYPD
$55M
| $3.49 | $720 |
20,530%
upside
| Overweight |
30 Jul ‘21
4 years ago |
|
|
44
Emergent Biosolutions
EBS
$403M
| $8.26 | $110 |
1,232%
upside
| Overweight |
17 Jul ‘20
5 years ago |
|
45
ANI Pharmaceuticals
ANIP
$2.06B
| $98.46 | $40 |
59%
downside
| Neutral |
7 May ‘20
5 years ago |
|